— Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — — Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year ...

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Overseen by a newly appointed CEO, genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Social media is speculating about the idea that Exact Sciences would buy Invitae. Investors should pinch themselves out of the daydream. One of the most important lessons of the stock-market ...

SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading ...